Mantra Pharma solidifies its position in the Canadian industry by launching M-Amoxi Clav

19 October, 2022

Quebec pharmaceutical company Mantra Pharma is pleased to announce the approval of the all-new M-Amoxi Clav (400 mg/57 mg per 5 mL) on the Canadian market, which is expected to arrive by the end of the year 2022. The company will thus become the only one offering a generic alternative to Clavulin®-400 (by GSK) to patients and healthcare professionals. This is an outstanding industry opportunity, and Mantra Pharma is thrilled to finally offer a therapeutic substitute, at a price that’s affordable for individuals and for public and private drug insurance plans.

 

In the wake of the pandemic, there has been a significant upsurge in antibiotic prescriptions, increasing the demand on laboratories for this type of product. This situation once again shows how important it is to diversify supply sources, particularly for generic drugs, to support the health network.

 

The launch of M-Amoxi Clav also represents a significant innovation for Mantra Pharma. This is the first oral solution in the Canadian pharmaceutical company’s drug offering, joining its wide range of tablets and eye solution products. “Mantra continues to diversify its portfolio and broaden its scope of action, to consolidate its presence on the Canadian market,” explained Jean-François Letarte, President of Mantra Pharma.

 

“It is important to us to help improve the availability and accessibility of multiple drug treatment options for Canadians, to better meet their needs while contributing to greater pharmaceutical autonomy in this segment,” said Maxime Deslauriers, Vice-President, Business Development and Scientific Affairs.

 

A few weeks ago, Mantra Pharma announced the addition of M-Apixaban to its portfolio, another molecule in high demand in the network.

 

About M-Amoxi Clav 400 mg/57 mg per 5 mL

The generic drug offered by Mantra Pharma is a compound of two molecules: amoxicillin and clavulanic acid. It is offered in powder form for oral suspension (drinkable) and is a faithful equivalent to the original, in terms of its contents, its format, and appearance.

 

About Mantra Pharma

Mantra Pharma develops and distributes generic drugs and over-the-counter pharmaceutical products. It also markets its own brands (mcal, Denta, Eczederm, and Urederma) in Quebec and Canadian pharmacies. The company has two business locations, in Lévis and Brossard, and employs over 115 people.

 

-30-

 

For more information, please contact Dominic Martel, Marketing Director, by email at dmartel@mantrapharma.ca or phone at 514-805-9054.

Nouvelles similaires

21/09/2022

Expansion continues with the launch of 6 products, including M-Apixaban

Since the beginning of 2022, Mantra Pharma has launched several new products, planning to offer...

Learn more
Photo 5 associés à Lévis pelletée de terre
10/01/2021

Mantra Pharma opens its new distribution centre

It is with great pride that Mantra Pharma's Lévis team opened its new warehouse and...

Learn more